These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30601074)

  • 21. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
    J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent development in the strategies projected for chikungunya vaccine in humans.
    Goyal M; Chauhan A; Goyal V; Jaiswal N; Singh S; Singh M
    Drug Des Devel Ther; 2018; 12():4195-4206. PubMed ID: 30573950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutics and vaccines against chikungunya virus.
    Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
    Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.
    Yang S; Fink D; Hulse A; Pratt RD
    Vaccine; 2017 Sep; 35(37):4851-4858. PubMed ID: 28760614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses.
    Prow NA; Liu L; Nakayama E; Cooper TH; Yan K; Eldi P; Hazlewood JE; Tang B; Le TT; Setoh YX; Khromykh AA; Hobson-Peters J; Diener KR; Howley PM; Hayball JD; Suhrbier A
    Nat Commun; 2018 Mar; 9(1):1230. PubMed ID: 29581442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New viral vectors for infectious diseases and cancer.
    Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
    Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fighting back against chikungunya.
    Rudd PA; Mahalingam S
    Lancet Infect Dis; 2015 May; 15(5):488-9. PubMed ID: 25739877
    [No Abstract]   [Full Text] [Related]  

  • 29. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
    Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
    Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses.
    Silva JVJ; Lopes TRR; Oliveira-Filho EF; Oliveira RAS; Durães-Carvalho R; Gil LHVG
    Acta Trop; 2018 Jun; 182():257-263. PubMed ID: 29551394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines.
    Salazar-González JA; Angulo C; Rosales-Mendoza S
    Vaccine; 2015 Jul; 33(31):3650-8. PubMed ID: 26073010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine.
    Tschismarov R; Zellweger RM; Koh MJ; Leong YS; Low JG; Ooi EE; Mandl CW; Ramsauer K; de Alwis R
    JCI Insight; 2021 Nov; 6(21):. PubMed ID: 34582377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate.
    Plante KS; Rossi SL; Bergren NA; Seymour RL; Weaver SC
    PLoS Negl Trop Dis; 2015; 9(9):e0004007. PubMed ID: 26340754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse event following live attenuated chikungunya vaccine in a cynomolgus macaque with pre-existing chronic hydrocephalus.
    Peterson TA; MacLean AG; Russell-Lodrigue KE; Didier PJ; Weaver SC; Roy CJ
    J Med Primatol; 2019 Aug; 48(4):257-259. PubMed ID: 30945306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A patent perspective on chikungunya.
    Dapurkar D; Telang M
    Acta Trop; 2019 Nov; 199():105131. PubMed ID: 31401192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
    Volz A; Sutter G
    Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine and Therapeutic Options To Control Chikungunya Virus.
    Powers AM
    Clin Microbiol Rev; 2018 Jan; 31(1):. PubMed ID: 29237708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies.
    Deeba F; Islam A; Kazim SN; Naqvi IH; Broor S; Ahmed A; Parveen S
    Pathog Dis; 2016 Apr; 74(3):. PubMed ID: 26657109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.